Miami, FL – October 8, 2020 (EmergingGrowth.com NewsWire) — EmergingGrowth.com, a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies, reports on PetVivo Holdings, Inc. (OTCQB: PETV).
24/7 Wall St. just released an article discussing medical technology and healthcare stocks that could be favorable going into 2021.
It mentions how technology has been the engine driving stock market performance, and now we are seeing a seismic shift to health care.
A new standard in the industry is seemingly moving towards working from home hence, medical technology companies are becoming more attractive.
Here are their top five picks:
AbbVie Inc. (NYSE: ABBV) – Shareholders receive a 5.42% dividend. Jefferies has a $107 price target for the shares, but the Wall Street consensus target is $109.12
Boston Scientific Corp. (NYSE: BSX) – The Jefferies price target of $46 is in line with the $46.29 consensus target.
Medtronic PLC (NYSE: MDT) – Medtronic stock investors receive a 2.23% dividend. The $120 Jefferies price target compares to the $115.83 consensus target.
Stryker Corp. (NYSE: SYK) Shareholders receive a 1.10% dividend and Jefferies has set a $225 price target.
Zimmer Biomet Holdings Inc. (NYSE: ZBH) Shareholders receive just a 0.72% dividend but the Jefferies price target is $167.
Here is one company in the Med Tech space that the article doesn’t mention and with its recent developments, it needs to be on your watch list.
Have a look at PetVivo (OTCQB: PETV). They just opened a state of the art medical device manufacturing facility in Edina Minnesota
The new PetVivo medical device facility, primarily dedicated to the manufacture of its veterinary medical device for the treatment of osteoarthritis (OA), KUSH™ will serve as the primary location for PetVivo medical device operations, which provides manufacturing capabilities to produce up to 500,000 syringes of Kush that could generate over $100 million in revenue annually.
KUSH, PETV’s lead product is a veterinarian-administered intraarticular injection for the treatment of osteoarthritis in dogs and horses is scheduled for expanded commercial sales and the development of its proprietary mucoadhesive active agent delivery products.
Sales in the $4.8 billion dog and horse therapeutics market is expected to begin shortly.
The facility includes over 600 square feet of state-of-the-art ISO 5, ISO 7 and ISO 8 cleanroom space, with plans for additional expansion and is dedicated exclusively to medical device manufacturing and product development. It is staffed with a highly skilled team, led by a seasoned management team having medical device manufacturing and engineering backgrounds.
Pet Vivo (OTCQB: PETV) also has a portfolio of 19 patents that protect the company’s pipeline of 16 products for the treatment of animals and people.
PetVivo has yet to attract the attention of the ETF’s but the company did just announce regarding their patent that “Our biomaterial technology and the claims issued in this patent provides us extremely comprehensive coverage”
PetVivo is an emerging biomedical device company leveraging the investments in the human biomaterials and medical device industries to commercialize therapeutics to pets.
Currently trading at around $.60 per share, with a market cap coming in at around $16 million, the stock was recently given a target price of between $1.74 and $2.32 per share by Marble Arch Research. You can download the full report here:
Download the full report here
Marble Arch Research notes that PetVivo achieved a major funding milestone last month, removing the main obstacle to its product commercialization goals. Commercial production of its disruptive osteoarthritis treatment device, Kush®, for canines and equines, a market we estimate is worth ~$3BN in the US alone, is due to commence in September 2020.
The report continues “At ~1x FY23 sales, the stock is substantially undervalued relative to its comps mostly trading in a comparable 3X-4X P/S multiple range.”
Just recently a new successful Kush study came to light when Just 4 weeks ago, Fender Bender, a racehorse suffering from osteoarthritis, was put up for sale and claimed for $3,000.00 and the new owner treaded him with PetVivo’s Kush. Fender Bender won at Canterbury Park on August 4, 2020.
PetVivo is benefiting from trials on the human side with a lower barrier to approval for pets.
According to The American Pet Products Association, almost 85 million households have a pet and over the last 30 years pet ownership has gone from 56% to 68% of all households.
It seems that PetVivo has value here. If you’re looking for a biotech that has not enjoyed a massive run yet, Pet Vivo may be the solution.
EmergingGrowth.com is a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies. Through its evolution, EmergingGrowth.com found a niche in identifying companies that can be overlooked by the markets due to, among other reasons, trading price or market capitalization. We look for strong management, innovation, strategy, execution, and the overall potential for long- term growth. Aside from being a trusted resource for the Emerging Growth info-seekers, we are well known for discovering undervalued companies and bringing them to the attention of the investment community. Through our parent Company, we also have the ability to facilitate road shows to present your products and services to the most influential investment banks in the space.